



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 13/00, C12N 15/15, 15/85 C12N 5/10, A61K 37/64	A1	(11) International Publication Number: WO 91/00291 (43) International Publication Date: 10 January 1991 (10.01.91)
(21) International Application Number: PCT/EP90/01026 (22) International Filing Date: 23 June 1990 (23.06.90) (30) Priority data: 89201675.9 26 June 1989 (26.06.89) EP (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant (for all designated States except US): AKZO N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only) : DIJKEMA, Reinder [NL/NL]; Pensionarisstraat 6, NL-5345 ML Oss (NL). VISSER, Arie [NL/NL]; Witte Hoeflaan 28, NL-5343 EH Oss (NL).		(74) Agent: HERMANS, Franciscus, Guilielmus, Maria; Postbus 20, NL-5340 BH Oss (NL). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SERPIN VARIANTS (57) Abstract <p>Modified antithrombin III variants are developed which contain amino acid substitutions in the region comprising amino acids 384-396. In this region one or more amino acids are replaced by the corresponding amino acid(s) grouped around the factor Xa cleavage site in factor II related to the formation of meizothrombin. These amino acid substitutions result in altered heparin-dependent inhibitory effect of the modified antithrombin III vis-à-vis the factors IIa and Xa, respectively.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

Serpin variants

The invention is concerned with a modified antithrombin III (ATIII) polypeptide, a polynucleotide sequence coding therefore, a recombinant vector containing such a polynucleotide sequence, a method for the preparation of said ATIII polypeptide, as well as a pharmaceutical product containing the modified ATIII polypeptide.

Blood clotting is a dynamic process wherein a great number of enzymes and factors cooperate ultimately leading to a conversion of the fibrinogen circulating in the blood into a network of fibrin aggregates.

These blood clotting enzymes are activated consecutively and under each others action. The conversion of fibrinogen into fibrin takes place under direct action of thrombin (factor IIa), which in turn is formed from prothrombin (factor II), under the action of an enzyme complex containing among others factor Xa. Both factor IIa and factor Xa belong to the enzyme class serine endopeptidases. The activities of these factors leading to the conversion of fibrinogen into fibrin in turn are balanced by the so-called serine proteinase inhibitors (serpins). One of the most well-known serpins is antithrombin III, a protein able to bind to both factor IIa and factor Xa and then form a stabile enzyme-pseudosubstrate complex with these respective factors. The formation of such a complex is stimulated by heparin, and leads to reduction of the amounts of factor IIa and factor Xa available for fibrinogen conversion.

This stimulation is the basis of the therapeutic use of heparin.

However, a disadvantage of the use of heparin is that both factors IIa and Xa are inactivated to an about equal extent. This results in a relatively small therapeutic margin for heparin. Inhibition of one of the coagulation factors would improve this therapeutic margin. Therefore the present invention is concerned with modified ATIII polypeptides that in a heparin-dependent way can specifically inactivate either of the two enzymes.

A modified ATIII polypeptide according to the invention is characterized by an amino acid sequence which differs from the sequence of natural mature ATIII protein (represented in figure 1 as cDNA sequence) to such an extent that at least one of the amino acids in the region comprising amino acids no. 384-396 is replaced by the corresponding amino acid(s) grouped around the factor Xa cleavage-site in prothrombin (factor II) related to the formation of meizothrombin. These corresponding amino acids of factor II are represented in figure 2, together with the indicated polypeptide region of ATIII. Advantageously, one or more of the amino acids no. 384-389, 394, and 396 of ATIII are substituted according to the following scheme:

Ala ³⁸⁴ →	Glu
Ser ³⁸⁵ →	Leu
Thr ³⁸⁶ →	Leu
Ala ³⁸⁷ →	Glu
Val ³⁸⁸ →	Ser
Val ³⁸⁹ →	Tyr
Ala ³⁹¹ →	Asp
Ser ³⁹⁴ →	Ile
Asn ³⁹⁶ →	Glu

Modified ATIII polypeptides according to the invention are exemplified in figure 2 as mutants 1-10.

The abovementioned substitutions result in remarkable shifts in the biochemical characteristics of the polypeptide.

In the presence of heparin the mature unmodified ATIII shows irreversible inhibition of the activities of both factors IIa and Xa. In contrast, polypeptides according to the invention wherein at least one of the amino acids no. 384-389 and 391 is replaced belong to the so-called type IIa inhibitors: in the presence of heparin they show a conserved irreversible inhibition of factor IIa, whereas their irreversible inhibition of factor Xa is lost (figure 3).

On the other hand, polypeptides wherein at least one of the amino acids no. 391, 394 and 396 is replaced belong to the so-called type Xa inhibitors: in the presence of heparin they show a conserved irreversible inhibition of factor Xa, whereas their irreversible inhibition of factor IIa is lost (figures 3 and 4). In particular, a single amino acid substitution at position 394 can be solely responsible for the conservation of irreversible inhibition of factor Xa and the loss of irreversible inhibition of factor IIa. Modified ATIII polypeptides according to the invention are exemplified in figure 5 as mutants 11-18. The size and/or hydrophilicity of the amino acid at position 394 determines the heparin-dependent inhibition profile of the ATIII polypeptides (figure 6).

Hence, it has been found that substitution in ATIII of the amino acids in the region 384-396 offers the possibility to specifically modulate the heparin-dependent activity of the polypeptide.

The ATIII variants according to the present invention can be applied therapeutically to influence blood clotting disorders, more specifically e.g. deep venous thrombosis, disseminated intravascular coagulation, and septic shock by either i.v. or s.c. route.

The polypeptides according to the invention can be prepared with the aid of recombinant DNA technology. Herein a polynucleotide, coding for such a polypeptide is brought to expression. Such a polynucleotide can be prepared e.g. by modifying a polynucleotide sequence coding for ATIII by nucleotide substitutions in such a way that the resulting polynucleotide codes for a polypeptide according to the present invention. Another possibility is to synthesize a polynucleotide coding for the desired polypeptide, using known polynucleotide synthesis techniques. It goes without saying that both techniques mentioned also can be combined, resulting in a polynucleotide consisting partially of natural and partially of synthetic segments.

The polynucleotide either may code for the continuous stretch of the desired polypeptide or may code for two or more exons (each coding for a segment of the desired amino acid sequence) interrupted by one or more so-called introns (non-coding parts, which are excised during the process of expression of the polypeptide). Of course, such a polynucleotide containing exons can only be used successfully in eukaryotic cells.

The abovementioned polynucleotides according to the invention are transferred to a suitable prokaryotic or eukaryotic, advantageously a mammalian, host cell by first incorporating the polynucleotide into a vector and then transforming the host with this recombinant vector. In this transformed host the polynucleotide is located under the control of other polynucleotide sequences which regulate expression and where appropriate secretion of the polypeptide product.

The polynucleotide can be present in the host in an autonomously replicating vector, or can be stably integrated in the genetic material of the host.

It goes without saying that instead of the said modified AT III polypeptides use can be made also of smaller polypeptides containing the region of AT III essential for inhibition of factor IIa or factor Xa and containing the amino acid substitution(s) mentioned above. These polypeptides can be prepared by recombinant DNA technology or by conventional peptide synthesis.

Example

METHODS

RNA preparation

Total RNA was extracted from either human fetal or adult liver samples by the guanidinium-phenol method (Chirgwin et al, Biochemistry 18, 5294, 1979) followed by oligo (dT) cellulose chromatography for selection of poly A⁺ mRNA (Maniatis et al., Cold Spring Harbor Laboratory "Molecular Cloning: A Laboratory Manual", 1982).

cDNA synthesis and cloning

Complementary DNA was prepared according to a published procedure (Gubler and Hoffman, Gene 25, 263, 1983), provided with Eco RI linkers (Pharmacia), and ligated into phage λ gt10 (Promega). In vitro packaging, titration of recombinant phage in E. coli BNN102, and preparation of library DNA onto nitrocellulose filters was as described (Huynh et al., DNA Cloning Techniques "A Practical Approach", 1984; Maniatis et al., *ibid.*).

Clone identification

Oligodeoxynucleotides were synthesized using the phosphoramidite method on an Applied Biosystems 381A DNA synthesizer. A complementary probe was synthesized comprising a conserved region within human serine proteinase inhibitors (e.g. serpin antithrombin III: position 1358-1382 in figure 1). Low stringency conditions for hybridization and washing were as described (Ragg, Nucl. Acids Res. 14, 1073, 1986). A partial cDNA clone was then used as nick-translated probe (Maniatis et al., *ibid.*) to obtain full-length cDNAs.

Site directed mutagenesis

Oligonucleotide directed mutagenesis was performed using a cDNA fragment cloned in M13mp18/19 as a template essentially as described (Nisbet and Beilharz, Gene Anal. Techn. 2, 23, 1985). The uracil containing phage M13mp18/19 templates were prepared by their growth on *E. coli* RZ1032 (*dut*⁻, *ung*⁻) as mentioned (Kunkel, Proc.Natl.Acad.Sci. USA 82, 488, 1985). Mutants were screened by determining their nucleic acid sequence (Sanger et al., Proc. Natl. Acad. Sci. USA 74, 5463, 1977).

Construction of expression plasmid

Wild type and variant antithrombin III genes were inserted in the unique restriction endonuclease BamHI site of the vector pKCR (O'Hara et al., Proc. Natl. Acad. Sci. USA, 78, 1527, 1981) in which the last exon region of the rabbit β -globin gene was removed by digestion with restriction endonuclease EcoRI and BglII, filling in, and religation (position 1122-1196; Van Ooyen et al., Science 206, 337, 1979) and replacement of pBR322 for pBR327 sequences.

Mammalian cell expression and affinity purification

For transient expression recombinant constructs were introduced by the DEAE-chloroquine method (Luthman and Magnusson, Nucl. Acids Res. 5, 1295, 1983) in COS cells (Gluzman, Cell 23, 175, 1982).

Serum-free culture supernatants derived 24-72 h posttransfection were concentrated by Amicon YM10 filtration and dialyzed against 0.05 mol/l Tris-HCl pH 8.0, 0.1 mol/l NaCl.

For stable transformation recombinant constructs and pSV2neo (Colbère-Garapin et al., J.Mol.Biol. 150, 1, 1981) were introduced by the calcium phosphate precipitation method (Graham and van der Eb, Virology 52, 456, 1973) in CHO cells. To select CHO transfectants for the stable integration and expression of the neo gene, the antibiotic G418 (Gibco) was added 24 hours post-transfection at a concentration of 1 mg/ml. After 14 days, production of ATIII by pools of G418-resistant colonies was monitored by an ATIII-specific ELISA using goat anti-human ATIII IgG (Sera Lab), rabbit anti-human ATIII IgG (Dakopatts), and sheep anti-rabbit IgG HRP conjugate. 2.5×10^6 Cells were seeded and grown for 48 hours in medium containing 10% foetal calf serum. After washing serum-free culture supernatants were harvested after an additional 48 hours and concentrated/dialyzed as mentioned above. Low-affinity monoclonal antibody AATR-1 (Interferon Sciences) coupled to tresyl-activated Sepharose (Pharmacia) was added to the processed supernatant and incubated for 4 hours at room temperature. Elution of bound ATIII was performed for 10 minutes in a volume of 1 ml of 3 mol/l NaSCN, 0.01 mol/l Tris-HCl pH 8.0. Immediately after elution, samples were dialyzed against 0.05 mol/l Tris-HCl pH 8.0, 0.1 mol/l NaCl. The concentration of ATIII was determined by the above-mentioned ELISA.

Inhibition assays

The heparin-dependent factor X_2 and factor II_2 inactivating potency of antithrombin III variants has been investigated with the help of the continuously monitored enzyme inactivation assay (Tian and Tsou, Biochemistry 21, 1028, 1982). They are expressed as the percentage of inhibition relative to the wild type ATIII.

RESULTS

- A recombinant phage containing part of the antithrombin III structural gene was obtained from a human fetal liver cDNA library using the conserved serpin probe. Its ATIII origin was confirmed by positive hybridization with a reactive site oligonucleotide probe (position 1253-1294 in figure 1) as well as DNA sequence analysis. The partial cDNA ATIIICDNA1 extends from position 887 to 1472. Two nucleotide differences were found when ATIIICDNA1 was compared to the ATIII cDNA reported by Bock et al. (Nucl. Acids Res. 10, 8113, 1982); C at position 1049 and T at position 1317 both differences are silent mutations not changing the corresponding amino acid codons. The insert of ATIIICDNA1 was used as a probe in subsequent screening of a human adult liver cDNA library resulting in ATIIICDNA2 extending from position 75 to 1479 (Bock et al., *ibid.*). The incomplete ATIII leader sequence was replaced by a synthetic DNA leader derived from the published ATIII cDNA sequence (Bock et al., *ibid.*). In addition, upstream of the ATIII leader sequence a suitable restriction endonuclease EcoRI site was positioned at position -10 (5'-GAATTCACCATG-3'). The complete ATIII cDNA cassette therefore consists of the following regions: i EcoRI (position -10) towards SacII (position 130) derived from synthetic origin, ii SacII (position 130) towards NcoI (position 935) derived from ATIIICDNA2, and iii NcoI (position 935) towards EcoRI

(position 1474) derived from ATIIIcDNA1. All fragments were ligated in the unique restriction endonuclease EcoRI site of pBR327.

- Inspection of the ATIII cDNA sequence around the reactive centre (P-region) indicate the existence of surrounding restriction endonuclease PvuII (position 1241) and StuI (position 1312) sites. Since an additional restriction endonuclease PvuII site is present at position 1096 this was deleted by site directed mutagenesis of residue G₁₁₀₁ into T₁₁₀₁, disturbing the restriction endonuclease PvuII recognition site, but still leaving the amino acid codon intact (CTG → CTT: Leu). Mutations introduced in the reactive centre P-region of ATIII can be performed by the replacement of the internal PvuII - StuI fragment (position 1241 to 1312) by a synthetic P-region of choice.

- Mutations introduced into the ATIII reactive centre P-region are derived from the human prothrombin gene (Degen and Davie, Biochemistry 26, 6165, 1987). Prothrombin participates in the final stage of clot formation since it is activated to thrombin by factor X_a. Selection of prothrombin sequences known to be physiological substrates for factor X_a and integration of (parts of) these sequences within the ATIII reactive centre P-region influences the inhibition profile of ATIII between factor X_a and factor II_a. The different synthetic P-regions, being hybrids between ATIII and prothrombin sequences, are illustrated in figure 2; they were used to replace the wild type PvuII - StuI fragment of the original ATIII cDNA backbone in pBR327 and confirmed by DNA sequence analysis.

- ATIII variants are evaluated for their inhibition profile in the following way. The variant ATIII containing fragments are isolated by digestion with restriction endonuclease EcoRI and filling in by DNA

polymerase. The blunt-ended fragments are then ligated in pPCR digested with restriction endonuclease BamHI and filling in by DNA polymerase. Correct orientation of the fragments with respect to the SV40 promoter was checked by restriction endonuclease mapping. The resulting recombinants were used for transient and stable expression in COS and CHO cells, respectively. Culture supernatants were tested for in vitro heparin-dependent inhibitory activity towards factor Xa and factor IIa.

- The ATIII P-region variants possessing different amino acid substituents derived from the prothrombin sequence (i.e. factor Xa cleavage site related to the formation of meizothrombin) are summarized in figure 2. As shown in figures 3 and 4 substitutions introduced in this way result in a remarkable shift in the heparin-dependent inhibition profile of ATIII towards factors IIa and Xa. With respect to the ATIII variant class being specific for factor Xa this can be accomplished by two independent ways. Either modification of at least amino acid residue 394 (Ser³⁹⁴ → Ile) or modification of amino acid residues 391 and 396 (Ala³⁹¹ → Asp and Asn³⁹⁶ → Glu) result in a common inhibition profile of the modified ATIII. In addition, the nature of the amino acid substitution at position 394 is crucial in conferring inhibitory profile to the ATIII polypeptide (figures 5 and 6). Therefore, other amino acid substitutions at position 394 that represent a large and/or hydrophilic character (Chotia, Ann.Rev.Biochem. 33, 537, 1984) predict a specificity of heparin-dependent inhibition towards factor Xa. Finally, modelling studies of factor Xa support the requirement of negatively charged residues within ATIII at the P3 and P3' position in order to form salt bridges with positively charged residues present in the S3 and S3' binding sites (Greer, J.Mol.Biol. 153, 1043, 1981).

Figure 1:

Antithrombin III cDNA sequence of reconstructed cassette.

Asterisks indicate differences observed with the ATIII cDNA sequence of Bock et al. (ibid.). Broken underlined restriction endonuclease sites were used for reconstruction experiments.

Underlined restriction endonuclease sites were used for P region replacement studies. The nucleotide G₁₁₀₁ indicated by 0 was mutagenized towards T₁₁₀₁ for deletion of the additional restriction endonuclease PvuII site.

The arrows indicate the start positions of partial ATIII cDNA clones obtained during this study.

Figure 2:

Antithrombin III P-region variants (PvuII-StuI: position 1244-1314)

Antithrombin III (ATIII; Bock et al., ibid)

Prothrombin (FII; Degen and Davie, ibid)

Amino acids that differ from the natural ATIII polypeptide are underlined.

Figure 3:

Heparin-dependent inhibition of factors IIa and Xa of ATIII and variants of culture supernatants derived from transfected COS cells.

WT = ATIII, COS = COS control and T = Tris-buffer.

Figure 4/Figure 6:

Heparin-dependent inhibition of factors IIa and Xa of ATIII and variants after affinity purification of culture supernatants derived from transfected CHO cells. WT = ATIII, C = CHO control, CT = transfected CHO control and T = Tris buffer.

Figure 5:

Antithrombin III P₁' variants

Amino acids that differ from the natural ATIII polypeptide are underlined.

Claims

1. Modified antithrombin III polypeptide, characterized in that it differs from natural mature antithrombin III protein in that at least one amino acid from the region comprising amino acids 384-396 is replaced by the corresponding amino acid(s) grouped around the factor Xa cleavage site in factor II related to the formation of meizothrombin, or a fragment thereof.
2. Modified antithrombin III polypeptide or a fragment thereof according to claim 1, wherein at least one of the following amino acid substitutions has taken place:
 - Ala³⁸⁴ → Glu
 - Ser³⁸⁵ → Leu
 - Thr³⁸⁶ → Leu
 - Ala³⁸⁷ → Glu
 - Val³⁸⁸ → Ser
 - Val³⁸⁹ → Tyr
 - Ala³⁹¹ → Asp
 - Ser³⁹⁴ → Ile.
 - Asn³⁹⁶ → Glu
3. Modified antithrombin III polypeptide or a fragment thereof according to claim 1 or 2, wherein at least the following amino acid substitution has taken place:
 - Ser³⁹⁴ → Ile.
4. Modified antithrombin III polypeptide or a fragment thereof according to claim 1 or 2, wherein at least the following amino acid substitution has taken place:
 - Ala³⁹¹ → Asp.
5. Modified antithrombin III polypeptide or a fragment thereof according to claim 1 or 2, wherein at least the following amino acid substitution has taken place:
 - Asn³⁹⁶ → Glu.

6. Modified antithrombin III polypeptide or a fragment thereof according to claim 4 or 5, wherein at least the following amino acid substitutions have taken place:
Ala³⁹¹ → Asp and Asn³⁹⁶ → Glu.
7. Nucleic acid sequence at least part of which is coding for a modified antithrombin III polypeptide or a fragment thereof according to claim 1-6.
8. Nucleic acid sequence according to claim 7, furthermore comprising at the 5' terminus of the sequence coding for the polypeptide a signal sequence and/or a promoter.
9. Vector comprising a nucleic acid sequence according to claim 7-8.
10. Host cell containing a nucleic acid sequence according to claim 7-8 or a vector according to claim 9.
11. Host cell according to claim 10 characterized in that it is derived from a mammalian cell.
12. Pharmaceutical preparation containing a polypeptide or a fragment thereof according to claim 1-6 as well as a pharmaceutically acceptable carrier.

FIGURE 1

0 ATGTA TTCCA ATGTG ATAGG AACTG TAACC TCTGG 5'-GAATT CCACC
 50 TCTTT TGTCC TTGCT GCTCA TTGGC TTCTG GGAAG GTTTA
 100 GGAGC CCTGT GGACA TCTGC ACAGC CAAGC CGCGG GACAT ACCTG TCACG
 150 CCCAT GTGCA TTTAC CGCTC CCCGG AGAAG AAGGC AACTG TCCCA TGAAT
 200 CTCAG AACAG AAGAT CCCGG AGGCC ACCAA CCGGC AACTG AGGAT GAGGG
 250 CCAAG GCCAA TTCCC GCTTT GCTAC CACTT TCTAT CAGCA GTGTC TGGGA ACTGT
 300 TCCAA GAATG ACAAT GATAA CATT TCTG TCACC CCTGA GTATC TCCAC
 350 GGCTT TTGCT ATGAC CAAGC TGGGT GCCTG TAATG ACACC CTCCA GCAAC
 400 TGATG GAGGT ATTTA AGTTT GACAC CATAT CTGAG AAAAC ATCTG ATCAG
 450 ATCCA CTTCT TCTTT GCCAA ACTGA ACTGC CGACT CTATC GAAAA GCCAA
 500 CAAAT CCTCC AAGTT AGTAT CAGCC AATCG CCTTT TTGGA GACAA ATCCC
 550 TTACC TTCAA TGAGA CCTAC CAGGA CATCA GTGAG TTGGT ATATG GAGCC
 600 AAGCT CCAGC CCCTG GACTT CAAGG AAAAT GCAGA GCAAT CCAGA GCGGC
 650 CATCA ACAA TGGGT GTCCA ATAAG ACCGA AGGCC GAATC ACCGA TGTCA
 700 TTCCC TCGGA AGCCA TCAAT GAGCT CACTG TTCTG GTGCT GGTTA ACACC
 750 ATTTA CTTCA AGGGC CTGTG GAAGT CAAAG TTCAG CCCTG AGAAC ACAAG
 800 GAAGG AACTG TTCTA CAAGG CTGAT GGAGA GTCGT GTTCA GCATC TATGA
 850 TGTAC CAGGA AGGCA AGTTC CGTTA TCGGC GCGTG GCTGA AGGCA CCCAG
 900 GTGCT TGAGT TGCCC TTCAA AGGTG ATGAC ATCAC CATGG TCCTC ATCTT
 950 GCCCA AGCCT GAGAA GAGCC TGGCC AAGGT GGAGA AGGAA CTCAC CCCAG
 1,000 AGGTG CTGCA GGAGT GGCTG GATGA ATTGG AGGAG ATGAT GCTGG TGGTC
 1,050 CACAT GCGCC GCTTC CGCAT TGAGG ACGGC TTCAG TTTGA AGGAG CAGCT
 1,100 GCAAG ACATG GGCCT TGTCG ATCTG TTCAG CCCTG AAAAG TCCAA ACTCC
 1,150 CAGGT ATTGT TGCAG AAGGC CGAGA TGACC TCTAT GTCTC AGATG CATTG
 1,200 CATAA GGCAT TTCTT GAGGT AAATG AAGAA GGCAG TGAAG CAGCT GCAAG
 1,250 TACCG CTGTT GTGAT TGCTG GCCGT TCGCT AAACC CCAAC AGGGT GACTT
 1,300 TCAAG GCCAA CAGGC CTTTC CTGGT TTTTA TAAGA GAAGT TCCTC TGAAC
 1,350 ACTAT TATCT TCATG GGCAG AGTAG CCAAC CCTTG TGTTA AGTAA AATGT
 1,400 TCTTA TTCTT TGCAC CTCTT CCTAT TTTTG GTTTG TGAAC AGAAG TAAAA
 1,450 ATAAA TACAA ACTAC TTCCA TCGGA ATTC - 3'



Figure 2

	385	390	P ₁	P ₁	395	400
ATIII	Ala Ala Ser Thr Ala Val Val Ile	Ala Gly Arg Ser Leu Asn Pro Asn Arg Val Thr Phe Lys Ala				
FII	Arg Glu Leu Leu Glu Ser Tyr	Ile Asp Gly Arg Ile Val Glu Gly Ser Asp Ala Glu Ile Gly Met				
Mutant 1	Ala Glu Leu Leu Glu Ser Tyr	Ile Asp Gly Arg Ile Val Glu Gly Ser Asp Ala Glu Ile Gly Ala				
Mutant 2	Ala Glu Leu Leu Glu Ser Tyr	Ile Asp Gly Arg Ser Leu Asn Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 3	Ala Ala Ser Thr Ala Val Val Ile	Asp Gly Arg Ile Val Glu Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 4	Ala Ala Ser Thr Ala Val Val Ile	Asp Gly Arg Ile Leu Glu Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 5	Ala Ala Ser Thr Ala Val Val Ile	Asp Gly Arg Ile Leu Asn Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 6	Ala Ala Ser Thr Ala Val Val Ile	Ala Gly Arg Ile Leu Glu Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 7	Ala Ala Ser Thr Ala Val Val Ile	Asp Gly Arg Ser Leu Glu Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 8	Ala Ala Ser Thr Ala Val Val Ile	Asp Gly Arg Ser Leu Asn Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 9	Ala Ala Ser Thr Ala Val Val Ile	Ala Gly Arg Ser Leu Glu Pro Asn Arg Val Thr Phe Lys Ala				
Mutant 10	Ala Ala Ser Thr Ala Val Val Ile	Ala Gly Arg Ile Leu Asn Pro Asn Arg Val Thr Phe Lys Ala				



Figure 3

3/6

Antithrombin III wild type (WT)



Antithrombin III mutant 2



Antithrombin III mutant 3






Figure 4

4/6




5/6

Figure 5

	390	P ₁	P ₁ '	395
ATIII	Val Ile Ala Gly Arg Ser	Leu Asn Pro Asn		
Mutant 10	Val Ile Ala Gly Arg <u>Ile</u>	Leu Asn Pro Asn		
Mutant 11	Val Ile Ala Gly Arg <u>Phe</u>	Leu Asn Pro Asn		
Mutant 12	Val Ile Ala Gly Arg <u>Tyr</u>	Leu Asn Pro Asn		
Mutant 13	Val Ile Ala Gly Arg <u>Leu</u>	Leu Asn Pro Asn		
Mutant 14	Val Ile Ala Gly Arg <u>Val</u>	Leu Asn Pro Asn		
Mutant 15	Val Ile Ala Gly Arg <u>Met</u>	Leu Asn Pro Asn		
Mutant 16	Val Ile Ala Gly Arg <u>Thr</u>	Leu Asn Pro Asn		
Mutant 17	Val Ile Ala Gly Arg <u>Gly</u>	Leu Asn Pro Asn		
Mutant 18	Val Ile Ala Gly Arg <u>Ala</u>	Leu Asn Pro Asn		

Figure 6



INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 90/01026

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: C 07 K 13/00, C 12 N 15/15, 15/85, 5/10, A 61 K 37/64

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System |

Classification Symbols

IPC⁵

C 07 K, C 12 N, A 61 K

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category ⁸	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	The Journal of Biological Chemistry, volume 263, no. 31, 5 November 1988, The American Society For Biochemistry and Molecular Biology, Inc., (US), A.W. Stephens et al.: "Site-directed mutagenesis of the reactive center (serine 394) of antithrombin III", pages 15849-15852 see the whole article --	1-12
A	Proc. Natl. Acad. Sci. USA, volume 84, no. 11, June 1987, (Washington, D.C., US), A.W. Stephens et al.: "Expression of functionally active human anti- thrombin III", pages 3886-3890 see the whole article --	7-11
A	EP, A, 0238473 (MONSANTO) 23 September 1987 see page 14, peptide 18; page 17, peptide 18; page 20, peptide 18	1-12

* Special categories of cited documents: ¹⁰ -----

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
of priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance: the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance: the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

8th October 1990

Date of Mailing of this International Search Report


31 OCT 1990

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Mme N. KUIPER



ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

EP 9001026
SA 38201

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/10/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0238473	23-09-87	JP-A- 62277399	02-12-87